Company Overview of Pall Corporation
Pall Corporation manufactures and markets filtration, separation, and purification products; and integrated systems solutions worldwide. Its Life Sciences segment provides technologies that facilitate the process of drug discovery, development, regulatory validation, and production, which are used in the research laboratories, pharmaceutical, biotechnology, and food and beverage industries, as well as in hospitals. It offers medical products to control the spread of infections in hospitals; cell therapy products; and filtration and purification technologies, associated hardware, and engineered systems for the development and commercialization of drugs, plasma, and vaccines. This segment also...
25 Harbor Park Drive
Port Washington, NY 11050
Founded in 1946
Key Executives for Pall Corporation
Chief Executive Officer, President and Interim President of Pall Industrial
Group Vice President and President of Pall Life Sciences
Senior Vice President and President of Biopharmaceuticals
Compensation as of Fiscal Year 2016.
Pall Corporation Key Developments
Pall Corporation Signs Commercial Collaboration Agreement with RoosterBio Inc
Oct 5 16
Pall Corporation announced the signing of a commercial collaboration agreement with RoosterBio Inc. The agreement will encompass a co-development and marketing partnership, delivering complete solutions for industrial-scale bioreactor expansion of human Mesenchymal Stem/Stromal Cells (hMSCs). These systems will enable the BioPharmaceutical industry to accelerate product development, reduce clinical translation timelines and ultimately streamline the commercialization pathway for stem cell-based therapies. Pall Life Sciences has continued expanding their Cell Therapy Manufacturing solutions portfolio, and this partnership furthers that aim. The complementary tools that RoosterBio and Pall contribute address a major challenge and current bottleneck in the multi-billion dollar Regenerative Medicine industry. Stem cell-based technologies are progressing rapidly through the clinic, but manufacturing of cellular therapeutics, including hMSCs, is significantly limited in scale. There are few standards or complete solutions currently marketed that enable simple, rapid development of scalable production methods of hMSCs. The strategic alliance between Pall and RoosterBio will provide total bioprocess solutions for cell culture of low cost, translation-friendly hMSCs for development of Cell Therapy, Tissue Engineering, Drug Screening, and Regenerative Medicine products.
Pall Life Sciences Extends the Range of Continuous, Single-Use Technologies to Improve Speed and Quality of Biopharmaceutical Production
Oct 4 16
Pall Corporation announced the launch of breakthrough technologies that for the first time enable integrated, process-scale continuous production of biotherapies in single-use formats. Biopharmaceutical manufacturers are increasingly incorporating continuous technologies to replace traditional batch methods in order to improve consistency, reduce production footprints and shorten lead times. Single-use technologies furthermore improve efficiencies by eliminating cleaning and validation requirements. CadenceTM BioSMB Process System. As part of Pall’s commitment to streamline purification scale-up from process development (PD) to process scale, Pall’s Cadence BioSMB Process System offers the industry’s first disposable flow path, continuous multi-column chromatography solution. Manufacturers using the Cadence BioSMB PD System can easily scale-up operations to the Cadence BioSMB Process System without changing process parameters, buffers, or sorbents—saving time and money. This technology transforms the entire chromatography process, with smaller column volumes and associated reductions in sorbents and buffer compared to traditional batch systems. Pegasus™ Prime Virus Removal Filters. Pall’s Pegasus Prime virus removal filters deliver consistent, robust virus retention to protect critical biotech manufacturing processes, assure drug quality and safeguard health. The Pegasus Prime family uses a filtration membrane with a unique surface morphology to provide robust capacity and high virus retention. Small scale devices, perfect for preliminary testing, scale-up and virus validation studies remove any virus filtration anxiety with the right format and the desired performance. The process scale filters are water-wet integrity testable and are supplied gamma irradiated to provide high flow and robust capacity, combining process simplification with sustainable process economics at all scales. Allegro™ STR Single-Use Bioreactor. To further reinforce its position in upstream manufacturing, Pall has extended its offering of single-use stirred tank bioreactors to now include a 2,000L bioreactor, with working volumes of 400 to 2,000 liters. Pall now has a family of three geometrically similar stirred tank bioreactors, all exceptionally ergonomic and intuitive to handle. Manufacturing, packaging and handling of the single-use biocontainer are designed to ensure its integrity. Supported by extensive long-term life tests, this greatly increases this system’s reliability for large-scale cell culture. Semi-automated biocontainer inflation and deflation procedures speed-up process turnover. In addition, this system’s compact footprint, with a height below three meters, makes it a great fit for most cleanrooms.
Pall Corporation Wins Major Water Reuse Project for City of Spokane
Sep 26 16
Pall Corporation announced that it has been selected as the membrane filtration provider for the City of Spokane, Washington’s Riverside Park Water Reclamation Facility upgrade. The upgrade is designed to meet stringent discharge limits for phosphorus, with a goal to improve the quality of the Spokane River as part of a major initiative within the city's Integrated Clean Water Plan. After a successful year-long, head to head pilot against submerged membrane technology conducted by CH2M, the Pall Aria FLEX system was selected based on significantly lower cost of operations. Key selection criteria that favored the Pall offering included higher water recovery, simple integrity testing, lower overall maintenance and ease of construction. In addition, the Pall system easily achieved the phosphorus limit goal of 18 parts per billion (ppb), consistently producing effluent between 9- 13 ppb. Overall, the Pall Aria FLEX pressurized membrane offering provided the lowest total cost of ownership while meeting the city’s treatment goals.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|